Founders
Randy W. Hamilton
Founder
Mr. Hamilton is a founder of Salix Pharmaceuticals, Inc., and served as Chairman of the Board, President, and Chief Executive Officer from the company's inception through November 1999. He remained
Executive Chairman of the Board until June 2002. Prior to founding Salix, Mr. Hamilton was Manager of Business Development for California Biotechnology, Inc. (now Scios, Inc.), and responsible for the commercial
aspects of several of the company's development projects, including human lung surfactant, drug delivery systems, genetic marker diagnosis, and growth factors. He was also responsible for establishing
strategic relationships with the Japanese pharmaceutical industry. Before joining California Biotechnology, Mr. Hamilton was Director of Strategic Planning and Business Development for SmithKline
Diagnostics, then a division of SmithKline Beckman, where he also held positions in market research and marketing information services. Mr. Hamilton received a B.A. in sociology from the California State
University, Long Beach. In 1998, Mr. Hamilton was named "Man of the Year" by the Crohn's and Colitis Foundation of America, Bay Area chapter.
Back to Top
Lorin K. Johnson, Ph.D.
Founder and Chief Scientific Liaison
Dr. Johnson is a founder of Salix and serves as Chief Scientific Liaison. Previously, he served as Senior Vice President and Chief Scientific Officer from November 1999 through September 2002. Prior to
that, he served as Vice President of Research from inception and was a member of the Company's Board of Directors from inception to June 2000. Prior to founding Salix, Dr. Johnson served as Director
of Scientific Operations and Chief Scientist at California Biotechnology, Inc., (now Scios, Inc.), where he headed research on anti-inflammatory therapeutics. Prior to joining California Biotechnology,
Dr. Johnson was an Assistant Professor of Pathology at Stanford University Medical Center. Dr. Johnson is the co-author of 75 journal articles and book chapters and is the co-inventor on 18 issued patents.
Dr. Johnson received his Ph.D. from the University of Southern California and was a post-doctoral fellow at the University of California, San Francisco.
Back to Top
Board of Directors
John F. Chappell
Chairman of the Board
Mr. Chappell has served as a member of the Board of Directors of Salix since December 1993 and as a member of its Audit and Compensation Committees since December 1994. He was named Chairman of the Board
in September 2003. In 1990, he founded Plexus Ventures, which specializes in business development and strategic transactions for clients in the biotechnology, pharmaceutical and drug delivery industries.
Prior to founding Plexus, Mr. Chappell served as Chairman of the Board of Worldwide Pharmaceuticals for SmithKline Beecham plc (now GlaxoSmithKline plc), where he was responsible for the multi-billion dollar ethical
pharmaceutical business, with 30,000 employees worldwide. During his 28 years at SmithKline Beecham, Mr. Chappell also headed the International Consumer Products (OTC) operations and the Corporate Planning
function. He has served on the Board of Directors of SmithKline Beecham, the Pharmaceutical Manufacturers Association (now PhRMA), and the Industrial Biotechnology Association (now BIO). Additionally, Mr. Chappell has
served on the Board of Directors of a number of biotechnology companies and is currently a member of Main Line Health Board of Governors. Mr. Chappell holds a B.A. from Harvard University and attended the Wharton
School of the University of Pennsylvania.
Back to Top
Thomas D'Alonzo
Mr. D'Alonzo joined the Salix Board of Directors in May 2000. He also serves on the Board of Directors of Amarillo Biosciences, Inc., and Plexigen,
Inc. Mr. D'Alonzo served as Chief Executive Officer and on the Board of Directors of MiMedx Group, Inc., from March 2007 to February 2009. From May 2006 to April
2007, Mr. D'Alonzo was Chief Executive Officer of DARA BioSciences, Inc., a pharmaceutical company, and he served on its Board of Directors from September
2005 to December 2008. From 2000 to 2007, Mr. D'Alonzo acted as an independent consultant. Prior to that, from 1996 to 1999, Mr. D'Alonzo served
as President and Chief Operating Officer of Pharmaceutical Product Development (PPD), Inc., a global provider of discovery and development services
to pharmaceutical and biotechnology companies. Before joining PPD, from 1993 to 1996, he served as President and Chief Executive Officer of GenVec,
Inc., a clinical-stage biopharmaceutical company. From 1983 to 1993, Mr. D'Alonzo held positions of increasing responsibility within Glaxo,
Inc., the U.S. division of GlaxoSmithKline plc, including President. Mr. D'Alonzo received a B.S. in Business Administration from the University of Delaware
and a J.D. from the University of Denver College of Law.
Back to Top
Richard A. Franco, Sr., R.Ph.
Mr. Franco joined the Salix Board of Directors in May 2000 with over 35 years of pharmaceutical senior executive, general management, and sales and marketing experience.
He is currently President of The Richards Group, Ltd., a healthcare advisory firm. Mr. Franco also serves on the Board of Directors of NeoMatrix, Inc., a breast care
diagnostics company, and the Research Triangle Chapter of the National Association of Corporate
Directors (NACD). Since 1997, Mr. Franco has served as Chairman, President, and Chief Executive Officer of DARA BioSciences, Inc., a publicly traded drug development company,
and as Chairman, President, Chief Executive Officer, and founder of LipoScience, Inc., a spectroscopic analysis company for clinical diagnostics. From April 1994 to April 1996, Mr. Franco
served as President and Chief Executive Officer of Trimeris, Inc., a publicly traded biopharmaceutical company. Previously, Mr. Franco served as a corporate officer and member of the Executive
Committee of Glaxo Inc., as well as Vice President and General Manager of Glaxo Dermatology, Vice President and General Manager of the Cerenex Division, Vice President
of Commercial Development, and Vice President of Marketing. Prior to joining Glaxo, Mr. Franco was with Eli Lilly and Company for 16 years. Mr. Franco received a pharmacy
degree from St. John's University and attended Long Island University for graduate work in pharmaceutical marketing and management.
Back to Top
William P. Keane
Mr. Keane joined the Salix Board of Directors in January 2004 and has more than 30 years of financial and executive experience primarily in the pharmaceutical and biotechnology
industries. Mr. Keane has a breadth of operational and strategic expertise, including international operations, mergers and acquisitions, and strategic analysis. Most recently,
as Chief Financial Officer at Genta, Inc., Mr. Keane was responsible for the financial, strategic, and information technology functions of this biopharmaceutical company as it
transitioned from a research and development focus to a commercial entity. In addition, Mr. Keane has served as Vice President of Sourcing, Strategy and Operations Effectiveness for
Bristol-Myers Squibb, Chief Financial Officer for Covance Biotechnology Services Inc., and Vice President of Finance, Global Pharmaceutical Manufacturing, for Warner-Lambert. During
his twelve-year career with Ciba-Geigy/Novartis, Mr. Keane held increasingly senior national and international financial and operational positions, culminating in
Director of Finance and Administration for the United Kingdom pharmaceuticals business of Novartis AG.
Mr. Keane received a B.A. in Microbiology from Rutgers College and an M.B.A. in Finance from the Rutgers University School of Management.
Back to Top
Carolyn J. Logan
Ms. Logan joined Salix in June 2000 as Senior Vice President of Sales and Marketing and was named President and Chief Executive Officer in July 2002. Ms. Logan has approximately 30
years of specialty pharmaceutical sales and marketing experience, including extensive experience building and/or rebuilding specialty pharmaceutical sales forces. Before joining Salix,
she served as Vice President of Sales and Marketing of the Oclassen Dermatologics division of Watson Pharmaceuticals, Inc., from May 1997 to June 2000, and as Vice President of Sales
from February 1997 to May 1997. Prior to that date, she served as Director of Sales of Oclassen Pharmaceuticals, Inc., from January 1993 to February 1997. Prior to joining Oclassen,
Ms. Logan held various sales and marketing positions of increasing responsibility with Galderma Laboratories, Ulmer Pharmacal, and Westwood Pharmaceuticals. Ms. Logan received a B.S.
in Biology and Dental Hygiene from the University of North Carolina at Chapel Hill.
Back to Top
Mark A. Sirgo, Pharm. D.
Dr. Sirgo joined the Salix Board of Directors in February 2008 with over 25 years of pharmaceutical industry experience spanning clinical drug development, licensing and business
development, marketing, and sales. He currently serves as President and Chief Executive Officer of BioDelivery Sciences International, Inc., (NASDAQ: BDSI), a specialty pharmaceutical
company. Prior to this position, he was a co-founder and Chief Executive Officer of Arius Pharmaceuticals. Prior to his involvement with Arius Pharmaceuticals, he spent 16 years in a
variety of positions of increasing responsibility in both clinical development and marketing at Glaxo, Glaxo Wellcome, and GlaxoSmithKline, including Vice President of International OTC
Development and Vice President of New Product Marketing. Dr. Sirgo was responsible for managing the development and FDA approval of Zantac 75, among other accomplishments. From 1996
to 1999, Dr. Sirgo was Senior Vice President of Global Sales and Marketing at Pharmaceutical Product Development (PPD), Inc., a leading global pharmaceutical contract research organization.
Dr. Sirgo received a B.S. in Pharmacy from the Ohio State University and a Doctorate from the Philadelphia College of Pharmacy and Science.
Back to Top
Executive Management Team
Carolyn J. Logan
President and Chief Executive Officer
Ms. Logan joined Salix in June 2000 as Senior Vice President of Sales and Marketing and was named President and Chief Executive Officer in July 2002. Ms. Logan has approximately 30
years of specialty pharmaceutical sales and marketing experience, including extensive experience building and/or rebuilding specialty pharmaceutical sales forces. Before joining Salix,
she served as Vice President of Sales and Marketing of the Oclassen Dermatologics division of Watson Pharmaceuticals, Inc., from May 1997 to June 2000, and as Vice President of Sales
from February 1997 to May 1997. Prior to that date, she served as Director of Sales of Oclassen Pharmaceuticals, Inc., from January 1993 to February 1997. Prior to joining Oclassen,
Ms. Logan held various sales and marketing positions of increasing responsibility with Galderma Laboratories, Ulmer Pharmacal, and Westwood Pharmaceuticals. Ms. Logan received a B.S.
in Biology and Dental Hygiene from the University of North Carolina at Chapel Hill.
Back to Top
Adam C. Derbyshire
Executive Vice President, Finance and Administration, and Chief Financial Officer
Mr. Derbyshire joined Salix in June 2000, bringing extensive pharmaceutical industry experience in finance, accounting, investor relations, and general corporate matters. Prior
to joining Salix, Mr. Derbyshire was Vice President, Corporate Controller, and Secretary of Medco Research, Inc., (acquired by King Pharmaceuticals, Inc., in February 2000) from
June 1999 to June 2000, and Corporate Controller and Secretary from September 1995 to June 1999. Prior to that, he served as Assistant Controller of Medco Research from October 1993
to September 1995. Mr. Derbyshire received a B.S. degree from the University of North Carolina at Wilmington and an MBA from the University of North Carolina at Charlotte.
Back to Top
William P. Forbes, Pharm.D.
Senior Vice President, Research and Development, and Chief Development Officer
Dr. Forbes has served as Vice President of Research and Development and Chief Development Officer at Salix since January 2005. Dr. Forbes has over 20 years of experience in
pharmaceutical development. Prior to joining Salix, Dr. Forbes served as Vice President of Clinical Development and Regulatory Affairs at Metabasis Therapeutics, Inc. Prior to that,
he served as a Group Leader at Otsuka America Pharmaceutical, Inc., since 1996, and held various senior management positions in clinical research at Otsuka since 1991. Before joining
Otsuka, Dr. Forbes served as Senior Clinical Research Scientist at Glaxo, Inc. Dr. Forbes has had responsibilities involving the clinical research and development of numerous new
chemical entities in a variety of therapeutic indications, including gastroenterology and infectious disease. Dr. Forbes received a Pharm.D. from Creighton University and conducted
post-doctoral work at the Creighton Cardiac Center and the Cardiovascular Clinical Research department at Glaxo.
Back to Top